Risk factor
Very high price volatility
Profitability factor
Very weak growth
About
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Buy
Sell